CYTOSORBENTS CORPORATION Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CYTOSORBENTS CORPORATION stock issued during period, value, new issues for the quarter ending 2025-03-31 was $5.39M, a 10028.49% increase year-over-year.
- CYTOSORBENTS CORPORATION stock issued during period, value, new issues for the quarter ending 2024-12-31 was $166.65K, a 98.63% decline year-over-year.
- CYTOSORBENTS CORPORATION stock issued during period, value, new issues for the quarter ending 2024-09-30 was -$41.00K, a 106.48% decline year-over-year.
- CYTOSORBENTS CORPORATION stock issued during period, value, new issues for the quarter ending 2024-06-30 was -$239.00, a 100.03% decline year-over-year.
- CYTOSORBENTS CORPORATION stock issued during period, value, new issues for fiscal 2024 was $178.65K, a 98.75% decline from fiscal 2023.
- CYTOSORBENTS CORPORATION stock issued during period, value, new issues for fiscal 2023 was $14.26M.
- CYTOSORBENTS CORPORATION stock issued during period, value, new issues for fiscal 2021 was -$90.00K, a 100.11% decline from fiscal 2020.
- CYTOSORBENTS CORPORATION stock issued during period, value, new issues for fiscal 2020 was $80.21M, a 11807.32% increase from fiscal 2019.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-03-31 | $5.39M 10-Q · filed 2025-05-14 | $5.52M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-12-31 | $166.65K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $178.65K 10-K · filed 2025-03-31 |
| 2024-09-30 | -$41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $12.16M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$239.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $12.83M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $53.24K 10-Q · filed 2025-05-14 | $13.61M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $12.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $14.26M 10-K · filed 2025-03-31 |
| 2023-09-30 | $632.39K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $776.29K 10-Q · filed 2024-08-13 | |
| 2023-03-31 | $698.43K 10-Q · filed 2024-05-09 | |
| 2022-03-31 | -$40.36K 10-Q · filed 2022-05-03 | |
| 2021-12-31 | -$90.00K 10-K · filed 2024-03-15 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $80.21M 10-K · filed 2023-03-09 |
| 2020-09-30 | $56.20M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $4.47M 10-Q · filed 2021-08-03 | |
| 2020-03-31 | $19.54M 10-Q · filed 2021-05-04 | |
| 2019-12-31 | $673.65K 10-K · filed 2022-03-10 | |
| 2018-12-31 | $209.56K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $14.13M 10-K · filed 2021-03-09 |
| 2018-09-30 | $587.40K 10-Q · filed 2019-11-05 | $15.63M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-06-30 | $7.28M 10-Q · filed 2019-08-06 | $16.70M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-03-31 | $6.05M 10-Q · filed 2019-05-07 | |
| 2017-12-31 | $1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $13.68M 10-K · filed 2020-03-05 |
| 2017-09-30 | $1.66M 10-Q · filed 2017-11-09 | |
| 2015-12-31 | $225.00K 10-Q · filed 2017-11-09 | $9.52M 10-K · filed 2018-03-08 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $9.41M derived: sum of 4 quarters · filed 2017-03-03 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $9.41M derived: sum of 4 quarters · filed 2017-03-03 |
| 2015-03-31 | $9.41M 10-Q · filed 2015-05-11 | $9.41M derived: sum of 4 quarters · filed 2017-03-03 |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-03 | $300.00K 10-K · filed 2017-03-03 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $1.00M derived: sum of 4 quarters · filed 2015-03-31 |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | $1.70M derived: sum of 4 quarters · filed 2015-03-31 |
| 2014-03-31 | $300.00K 10-Q · filed 2014-05-14 | $2.15M derived: sum of 4 quarters · filed 2015-03-31 |
| 2013-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | $2.30M 10-K · filed 2015-03-31 |
| 2013-09-30 | $700.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-06 | |
| 2013-06-30 | $449.97K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | |
| 2013-03-31 | $450.00K 10-Q · filed 2013-05-15 | |
| 2012-12-31 | $3.66M 10-K · filed 2014-03-31 | |
| 2012-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-13 | $2.26M derived: sum of 4 quarters · filed 2014-03-31 |
| 2012-03-31 | $1.16M 10-Q · filed 2012-05-15 | |
| 2011-12-31 | -$1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-31 | $2.64M 10-K · filed 2014-03-31 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14 | |
| 2010-12-31 | $750.00K 10-K · filed 2014-03-31 | |
| 2006-12-31 | $8.00M 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |